Pfizer Just Locked Next Growth Path: What Investors Should Know
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Learn which cash back cards offer the best deals and rewards. Make the most of your spending with these top choices.
27,977 articlesPfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Rising interest-rate expectations are shifting as traders weigh the impact of potential policy shifts. A Trump-led ea...
The S&P 500 is up this year, but history offers guidance on what comes next. Learn the patterns, risks, and practical...
The tokenized assets market is climbing to fresh records. This piece explains why May's momentum matters and how Ethe...
As 2026 unfolds, a new government analysis finds that majors tied to real-world demand offer strong pay and job stabi...
A leading investing author known for the stock market maestros concept argues that enduring gains come from disciplin...
As Congress stalls on federal AI regulation, states are advancing targeted laws on chatbot interactions, employer use...
A field-wide quantum ETF costs 0.40% and promises diversified exposure to IonQ and peers, challenging single-stock be...
High earners are pursuing a legal workaround—backdoor roth 401(K) conversions—to move after-tax 401(K) money into Rot...
Gas prices are reshaping how Americans travel. This article explains the surge in carpooling, highlights a stock buil...
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
A prominent hedge fund just sold its entire XPeng stake, triggering questions for everyday investors. Learn how to ev...